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Abstract 
Background: Sequestration of parasitized red blood cells from the peripheral circulation during an infection with 
Plasmodium falciparum is caused by an interaction between the parasite protein PfEMP1 and receptors on the surface 
of host endothelial cells, known as cytoadherence. Several lines of evidence point to a link between the pathology of 
severe malaria and cytoadherence, therefore blocking adhesion receptors involved in this process could be a good 
target to inhibit pRBC sequestration and prevent disease. In a malaria endemic setting this is likely to be used as an 
adjunct therapy by reversing existing cytoadherence. Two well-characterized parasite lines plus three recently derived 
patient isolates were tested for their cytoadherence to purified receptors (CD36 and ICAM-1) as well as endothelial 
cells. Monoclonal antibodies against human CD36 and ICAM-1 were used to inhibit and reverse infected erythrocyte 
binding in static and flow-based adhesion assays.
Results: Anti-ICAM-1 and CD36 monoclonal antibodies were able to inhibit and reverse P. falciparum binding of lab 
and recently adapted patient isolates in vitro. However, reversal of binding was incomplete and varied in its efficiency 
between parasite isolates.
Conclusions: The results show that, as a proof of concept, disturbing existing ligand–receptor interactions is possible 
and could have potential therapeutic value for severe malaria. The variation seen in the degree of reversing existing 
binding with different parasite isolates and the incomplete nature of reversal, despite the use of high affinity inhibi-
tors, suggest that anti-adhesion approaches as adjunct therapies for severe malaria may not be effective, and the 
focus may need to be on inhibitory approaches such as vaccines.
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Background
The understanding of the molecular mechanisms under-
pinning Plasmodium falciparum-infected red blood cell 
(pRBC) cytoadherence has provided a complex picture 
of pRBC. Adhesion to vascular endothelial cells (EC) is 
associated with the interaction of Plasmodium falci-
parum erythrocyte membrane protein 1 (PfEMP1) on 
the surface of red blood cells (RBC) and a range of host 
adhesion receptors expressed on microvascular EC. EC 
can express many different adhesion molecules on their 
surfaces that support adhesion of pRBC, including CD36, 
ICAM-1, EPCR, VCAM-1, E-selectin and PECAM-1 [1, 
2]. The role and relative importance of these receptors in 
sequestration is still not clear, but receptor cooperation/
synergism has been shown to enhance the binding [3, 4].
There is some evidence, although it is not supported 
by all studies, that interaction of PfEMP1 with ICAM-1 
is involved in the pathogenesis of cerebral malaria 
[5] while adhesion to CD36 has been associated with 
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uncomplicated malaria as well as non-cerebral severe 
malaria (see [6] for a review). More recent work has iden-
tified EPCR as being associated with severe malaria [2], 
including the possibility of structural conservation of the 
binding site on PfEMP1 that might support the develop-
ment of a vaccine [7, 8]. Therefore, blocking and disrupt-
ing pRBC adhesion to host receptors could reduce the 
probability of developing severe malaria (SM).
Interfering with the parasite/host interaction by target-
ing PfEMP1 may reduce cytoadherence. PfEMP1 consists 
of multiple domains [Cysteine-rich Interdomain Region 
(CIDR) and the Duffy Binding-like (DBL) domains] 
and previous work has shown that an anti-CIDR anti-
body can block binding of pRBC to immobilized CD36 
protein [9]. A specific PfEMP1 variant has been found 
expressed on pRBC associated with placenta malaria and 
subsequent studies based on the molecular characteri-
zation of this molecule (VAR2CSA) have derived cross-
reactive antibodies able to inhibit pRBC binding to CSA 
[10]. The CSA binding site has been identified and stud-
ies are underway to test vaccine candidates based on this 
structure [11]. For malaria infections in non-pregnant 
hosts, the control of expression of var genes that pro-
duce PfEMP1 proteins is complex [12] and results in a 
high degree of variability of PfEMP1 expression due to 
antigenic variation. Thus, the use of antibodies based 
on PfEMP1 fragments other than VAR2CSA will not be 
simple and will require further work to define key bind-
ing signatures. Some progress has been made in this area 
with cross-reactive antibodies defined for PfEMP1 DC4 
to ICAM-1 binding [13] and PfEMP1 DC8/DC13 binding 
to EPCR [7], including the structure of PfEMP1 showing 
dual binding specificity with these EC receptors [14].
The alternative to preventing interactions based on 
inhibition of PfEMP1 is by blocking endothelial recep-
tors, which may solve the problem of variability of 
PfEMP1 in this system. It has been shown previously that 
some mAbs can inhibit the interaction of pRBC to spe-
cific receptors on EC. For example, mAb OKM5, which 
has as its epitope the immuno-dominant region at amino 
acids 139–184 of CD36, is able to block cytoadherence 
of pRBC to CD36 [15, 16]. Adhesion to ICAM-1 can be 
inhibited using several different mAbs against ICAM-1 
[17, 18] such as mAb 15.2 against the L42 loop of domain 
1 of ICAM-1. This approach appears to work across dif-
ferent PfEMP1 variants, including field isolates [13, 19], 
suggesting some conservation of the host binding site.
Several published experiments have addressed inhibi-
tion of adhesion of pRBC by mAb, focussing on the pre-
vention of de-novo adhesion [20], but there have been 
very few studies looking at the potential to reverse exist-
ing pRBC cytoadherence [21]. Reversing pRBC seques-
tration has been considered as an attractive contributing 
strategy for the management of SM [22], as an adjunct 
to standard anti-parasite treatment. The rationale for 
reversing sequestration was based on the beneficial 
effects of administration of anti-malaria immunoglob-
ulins from adults with malaria to children with mild 
malaria in Thailand [23]. The results suggested that the 
antibodies inhibited cytoadherence to C32 melanoma 
cells and rosette formation. This may be a natural pre-
ventive mechanism against the severity of P. falciparum 
infection in the infected host, and the effect has been 
replicated in animal models [24], and in in vitro adhesion 
studies [21, 25]. In a squirrel monkey model of malaria 
[24], the administration of hyperimmune serum was rap-
idly followed by the swift appearance (30 min after injec-
tion) of previously adherent infected erythrocytes in the 
peripheral circulation and an impressive recovery from 
sickness. In vitro, adhesion of Thai isolates to C32 mela-
noma cells was reversed with Thai immune sera [21], and 
the adhesion of isolates from Malawi was reversed with 
a pool of local immune sera [25]. Adhesion to individual 
receptors can be reversed with monoclonal antibodies 
[26–29] or ligand peptide segments [30, 31]. Recently 
investigators have used a modified heparin compound, 
sevuparin [32], to reverse adhesion, although the mecha-
nism of action is not clear.
While the reversal of cytoadherence by human serum 
containing relevant antibodies, both in vitro and in vivo, 
suggests that a pool of high-titre malarial antibodies, 
shown to have reactivity with the surface of infected 
erythrocytes [25] could reverse adhesion in vivo, a double 
blind, placebo-controlled administration of the antibod-
ies as an adjunct to quinine (the best available anti-malar-
ial at the time) had no measurable observed effect on 
adhesion, and did not affect patient recovery [22]. The 
inherent difficulty with this approach is, at least in part 
(but see also [33]), the variable nature of PfEMP1 and, 
therefore, the complexity of the antibody pool to interfere 
with cytoadherence. As the host-parasite interaction has 
(at least) two components, another approach would be to 
block the host receptor, although this could have poten-
tially serious adverse effects if the target overlapped with 
a critical host function. Not enough is known about the 
details of the binding sites for all the host receptors but 
available data show the pRBC binding site on ICAM-1 
has discrete elements from the LFA-1 binding site [17], 
although the EPCR binding site uses the same region as 
that involved in the conversion of protein C to its acti-
vated form [2, 34, 35]. This study investigated whether 
antibodies to individual host receptors could reverse 
existing pRBC adhesion to endothelial cells under physi-
ological conditions, using the common adhesion recep-
tors ICAM-1 and CD36, both as purified proteins and in 
cellular context.
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Methods
Parasite culture
ItG [36] and C24 [37] laboratory parasite lines, which 
are well characterized for their binding to ICAM-1 and 
CD36 respectively [38], were cultured under standard 
conditions in RPMI 1640 medium supplemented with 
37.5  mM HEPES, 11  mM d-glucose, 0.2%  NaHCO3, 
25 μg/ml gentamycin sulfate, 2 mM l-glutamine and 10% 
pooled human serum at pH 7.2 in a gas mixture compris-
ing 96% nitrogen, 3% carbon dioxide, and 1% oxygen. 
The culture-adapted ICAM-1-selected [19] parasite lines 
GL6, P069 and 8146 [19] were also investigated in rever-
sal assays.
Endothelial cell culture
Human umbilical vein vascular endothelial cells 
(HUVEC) and human dermal microvascular endothelial 
cells (HDMEC) obtained from Promocell were cultured 
as per manufacturer’s procedures. Cells at passage 4–6 
were used for all experiments. Prior to use, cells were 
stimulated by addition of 1 ng/ml TNF for 18 h to allow 
enhanced ICAM-1 expression on the surface of the EC.
Plasmagel trophozoite enrichment
The parasite culture was centrifuged at 500g for 5  min 
and the pellet resuspended in a ratio of 2 volumes pellet 
to 3 volumes RPMI-based growth media without human 
serum (incomplete medium) and 5 volumes Plasmion 
(Fresenius Kabi), and allowed to settle for 20–30 min at 
37 °C. Trophozoite stage pRBC in the top layer were then 
washed three times in incomplete medium and the para-
sitaemia assessed by Giemsa-stained smear.
Selection of pRBC on ICAM‑1 purified protein
To increase the homogeneity of the ItG parasite popula-
tion, which expresses a PfEMP-1 variant with high affin-
ity for ICAM-1, the population was subjected to selection 
on ICAM-1 protein. 2.5 µg of ICAM-1 protein [39] was 
coated on 50  µl of protein A Dynabeads (Invitrogen) in 
400  µl of 1% bovine serum albumin (BSA) in PBS and 
incubated for 1 h at room temperature with gentle rota-
tion (15 rpm). Dynabeads were washed gently in 1% BSA/
PBS using a magnetic stand. 50 µl of ItG parasite culture 
synchronized and enriched using Plasmagel enrichment 
were incubated with the coated beads in 400  µl BSA/
PBS for 45 min at room temperature by gentle rotation. 
Unbound pRBC were removed and the bound pRBC 
washed three times with BSA/PBS using the magnetic 
stand. Beads were resuspended in 5 ml of complete RPMI 
media and transferred to a culture flask with the addition 
of 50 µl of washed red blood cells.
Inhibition and reversal assays with purified receptor 
under static conditions
Bacteriological petri-dishes (6  cm) coated with 50  μg/
ml CD36 and 50 μg/ml ICAM-1 protein spots [18] were 
pre-incubated with 1.5 ml of binding buffer (RPMI 1640 
medium with 25 mM HEPES, 11 mM d-glucose, 2 mM 
l-glutamine, pH 7.2) with or without 5 µg/ml αICAM-1 
antibody (clone 15.2; Santa Cruz) or 10  µg/ml αCD36 
antibody (clone FA6-152; abcam), at 37  °C for 30  min, 
before proceeding with the adhesion assay. The solu-
tions were aspirated, a parasite suspension of 3% parasi-
taemia and 1% haematocrit in binding buffer was added 
and incubated for 1 h at 37 °C rotating every 10 min. The 
petri-dish was washed 3–5 times with binding buffer, 
fixed using 1% glutaraldehyde for at least 1  h and then 
stained with 5% Giemsa for 30 min.
Reversal assays were carried out in a similar fashion, 
except that pRBC binding was performed without anti-
body. After the 3–5 washes in binding buffer, the dishes 
were incubated for a further 1  h with either binding 
buffer alone, or with the addition of 5  µg/ml αICAM-1 
antibody or 10 µg/ml αCD36 antibody, with gentle mix-
ing every 10  min. Dishes were washed with 4  ×  2  ml 
binding buffer, fixed in 1% glutaraldehyde and stained 
with Giemsa. All experiments were carried out with 
duplicate dishes each containing triplicate spots.
Reversal assays with purified receptor under flow 
conditions
Flow assays were carried out on microslides coated with 
ICAM-1 or CD36 at 50 µg/ml. Slides were prepared and 
assays carried out as described previously [38]. pRBC at 
3% parasitaemia and 1% haematocrit in binding buffer 
were flowed through the microslide for 5  min to allow 
for pRBC adhesion. Flow was continuous throughout 
the experiment at 0.05 Pa shear stress. After 5 min, the 
fluid was switched to binding buffer for 2 min to remove 
unbound pRBC and clear flow lines of pRBC. Timing 
was started with flowing through binding buffer contain-
ing no antibody (control), 5  µg/ml αICAM-1 or 10  µg/
ml αCD36 antibodies. The number of bound pRBC in 
six fields along the slide was counted at 0, 5, 10, 15 and 
20 min time points.
Inhibition and reversal assays with endothelial cells 
under static conditions
TNF-activated HUVEC or HDMEC were seeded on to 
coverslips (Nunc) and static cell assays carried out as 
previously described [38]. For the inhibition assay, the 
cells were pre-incubated with 1.5  ml of binding buffer 
with or without antibody (5 µg/ml αICAM-1 or 10 µg/ml 
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αCD36), at 37 °C for 30 min, before proceeding with the 
adhesion assay. pRBC (3% parasitaemia and 1% haemato-
crit) were allowed to bind and, following two dip washes, 
coverslips were placed in a gravity wash for 30 min. The 
coverslips were transferred to a second gravity wash for 
10 min, fixed in 1% glutaraldehyde and stained with 5% 
Giemsa.
For the reversal assay, after pRBC had been allowed 
to bind without any antibodies, and following two dip 
washes coverslips were placed cell-side up into a well 
containing binding buffer without (control) and with 
5  µg/ml αICAM-1 or 10  µg/ml αCD36 mAb. As above, 
after 30 min the coverslips were transferred to a second 
gravity wash for 10 min, fixed in 1% glutaraldehyde and 
stained with 5% Giemsa.
Following Giemsa staining, coverslips were dried and 
mounted on slides using DPX mountant (Sigma). Lev-
els of adhesion were quantified by microscopy under 
200× magnification. The number of adherent pRBC per 
 mm2 was calculated. All cell assays were carried out in 
triplicate.
Reversal assays with endothelial cells under flow 
conditions
Reversal of adhesion to HUVEC or HDMEC under 
flow conditions was carried out using TNF stimulated 
HUVEC or HDMEC grown overnight on chamber slides, 
and assays were carried out as previously described 
[38]. pRBC at 3% parasitaemia and 1% haematocrit were 
flowed through the slide for 5  min to allow for pRBC 
adhesion. Flow was continuous throughout the experi-
ment at 0.05 Pa shear stress. After 5 min pRBC suspen-
sion flow, the fluid was switched to binding buffer to 
remove unbound pRBC. Timing was started with flowing 
through binding buffer containing no antibody (control), 
5 µg/ml αICAM-1 or 10 µg/ml αCD36 mAb. The number 
of bound pRBC in six fields along the slide was counted 
at 0, 5, 10, 15 and 20 min time points.
Data analysis
For each experiment, the number of bound pRBC 
was calculated using Image-Pro Plus software (Media 
Cybernetics) and expressed as the mean bound pRBC/
mm2 ± standard deviation. Statistically significance com-
pared to the control (no Ab) was determined by t test.
Results
Effect of mAb inhibiting cytoadherence on purified protein
Plasmodium falciparum lab isolates ItG and C24 were 
selected for static and flow inhibition studies. Results 
show that ItG binding with αICAM-1 mAb (Fig.  1a, c) 
and C24 binding with αCD36 mAb (Fig. 1b, d) were sig-
nificantly inhibited (P  <  0.001) at levels of more than 
80% inhibition under static and flow conditions, show-
ing that binding of ItG and C24 was largely determined 
by ICAM-1 and CD36 respectively. Based on these 
results, we studied these two antibodies for their ability 
to reverse adhesion of already bound pRBC on protein 
(ICAM-1 and CD36). αICAM-1 mAb reverses binding 
of ItG and αCD36 mAb reverses binding of C24 under 
static conditions up to 80% (Fig. 1e, f, respectively), and 
under flow conditions approximately 60 and 35% (Fig. 2a, 
b, respectively), at 20 min timepoint.
Effect of mAb inhibiting cytoadherence on endothelial 
cells
Figure  3 shows that adhesion of ItG, which has strong 
binding to ICAM-1 and some to CD36, to HUVEC and 
HDMEC under static conditions was inhibited signifi-
cantly using αICAM-1, αCD36 and both αICAM-1 and 
αCD36 mAbs combined (P  <  0.01) (Fig.  3a, c) in com-
parison with ItG control (without antibody). Mean-
while C24 pRBC, which binds to CD36 but not ICAM-1, 
shows a reduction of binding after αCD36 mAb exposure 
(Fig.  3b). Results show that either αICAM-1 mAb indi-
vidually or in combination with the αCD36 mAb, pro-
duce the same level of pRBC inhibition for ItG adhesion 
to HDMEC. This supports earlier findings of coopera-
tive binding-interactions of some pRBC, including ItG, 
dependent on ICAM-1 in mediating efficient adhesion 
pRBC to the host endothelial cell [38], despite having 
some affinity for CD36 as well.
Effect of mAb reversing cytoadherence on endothelial cells
Based on the inhibition of binding to EC seen with the 
mAbs to CD36 and ICAM-1, reversal of adhesion of 
pRBC to HUVEC and HDMEC was investigated. To 
examine this effect static EC binding assays were con-
ducted and then treated with the relevant mAb(s) for 
another 1 h at 37 C. Figure 3d shows that the binding of 
ItG to HUVEC was reduced more than 90% after treat-
ment with 5 µg/ml αICAM1 mAb and the binding of C24 
to HDMEC was reduced 85% after treatment with 10 µg/
ml αCD36 mAb in comparison with the control (Fig. 3e) 
(both P < 0.05). The reduction of ItG binding to HDMEC 
by αICAM1 mAb was significant at ~75% (P < 0.05), but 
only 40%, and not significant, by αCD36 mAb in com-
parison with the control. The combination of αICAM1 
and αCD36 mAbs reversed the binding 66%, similar to 
αICAM1 mAb on its own (Fig. 3f ).
With the successful reversal of the sequestered pRBC 
on static cell based assays, endothelial cell flow based 
assays were performed following 20  min exposure to 
αICAM-1 and αCD36 mAbs, with significant reduction, 
and similar to the static assay, of ItG binding (Fig. 4) to 
HDMEC seen in comparison with the control.
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Effect of mAb reversing adhesion of patient isolates 
to endothelial cells
The effects of αICAM-1 and αCD36 mAbs on adhesion 
to TNF stimulated HDMEC were further investigated 
using culture-adapted patient isolates (GL6, P069 and 
8146), which have been characterized for their bind-
ing properties to ICAM-1 [19]. The results for the static 
assay show that αICAM-1 mAb alone is able to reverse 
Fig. 1 Inhibition of ItG binding to ICAM-1 under static (a) and flow (c) conditions. Binding in the absence of mAb (control) and after pre-incubation 
with αICAM-1 mAb at 5 µg/ml for 1 h. b Inhibition of C24 binding to CD36 under static and d flow conditions. Binding in the absence of mAb (con-
trol) and after pre-incubation with αCD36 mAb at 10 µg/ml for 1 h. Reversal of ItG binding to ICAM-1 (e) and C24 binding to CD36 (f) under static 
conditions. pRBC were allowed to bind to the protein for 1 h and binding was determined after subsequent incubation with 5 µg/ml αICAM-1 mAb 
(e) or with 10 µg/ml αCD36 mAb (f) for 1 h. Results expressed as mean bound pRBC/mm2 ± standard deviation. Control: without antibody
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P069 and GL6 binding, but not 8146 binding. Meanwhile, 
αCD36 mAb alone shows only slight decreases (15–25%) 
with all isolates’ binding to TNF-stimulated HDMEC. 
However, when both mAbs (αICAM-1  +  αCD36) are 
combined, a similar level of binding reduction was pro-
duced compared to either αICAM-1 or αCD36 mAb 
Fig. 2 Reversal of ItG binding to ICAM-1 (a) and C24 binding to CD36 (b) under flow conditions. pRBC were allowed to bind to the protein for 
5 min and binding was observed after flowing through binding buffer with αICAM-1 mAb at 5 µg/ml for 20 min (a) and αCD36 mAb at 10 µg/ml for 
20 min (b). pRBC bound were determined every 5 min and expressed as bound pRBC/mm2. Control: without antibody
(See figure on next page.) 
Fig. 3 a Inhibition of ItG binding to TNF-stimulated HUVEC under static conditions observed after pre-incubation with 5 µg/ml αICAM-1 mAb for 
1 h. b Inhibition of C24 to TNF-stimulated HDMEC under static conditions observed after incubation with 10 µg/ml αCD36 mAb for 1 h. c Inhibition 
of ItG binding to TNF-stimulated HDMEC under static conditions observed after incubation with 5 µg/ml αICAM-1 and 10 µg/ml αCD36 mAbs 
independently and the combination of both mAbs, for 1 h. d Reversal of ItG binding to TNF-stimulated HUVEC under static conditions. pRBC were 
allowed to bind to the cells for 1 h and binding was observed after incubation with 5 µg/ml αICAM-1 mAb for 1 h. e Reversal of C24 binding to TNF 
stimulated HDMEC under static conditions observed after incubation with 10 µg/ml αCD36 mAb for 1 h. f Reversal of ItG binding to TNF-stimulated 
HDMEC under static conditions observed after incubation with 5 µg/ml αICAM-1 mAb and 10 µg/ml αCD36 mAb or the combination of these 
mAbs, for 1 h. Results expressed as mean bound pRBC/mm2 ± standard deviation. Control, without antibody
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alone, depending on which one had the most effect as a 
single mAb treatment (Fig. 5).
Under flow conditions, the αICAM-1 mAb, showed loss 
of binding over 20 min for GL6 (70%) and PO69 (37%). 
However, αCD36 reversed binding by only 17–18%, while 
8146 binding was not reversed by either mAb (Fig. 6).
Discussion
Cytoadherence is thought to be a major virulence fac-
tor involved in the pathogenesis of severe malaria. It 
has been observed that most malaria deaths in children 
occur in the first 24–48 h of hospitalization, despite effec-
tive anti-malarial regimes (quinine or artemisinin) given 
Fig. 4 Reversal of ItG binding on TNF-stimulated HDMEC under flow conditions. pRBC were allowed to bind to the EC under flow for 5 min, 
washed for 2 min and then a solution of BB without mAb (control) or with 5 µg/ml αICAM-1 mAb, 10 µg/ml αCD36 mAb and a combination of both 
mAbs were used to reverse binding. The number of bound pRBC was counted at 0, 5, 10, 15 and 20 min. Results expressed as mean bound pRBC/
mm2 ± standard deviation
Fig. 5 Reversal of binding of the culture-adapted clinical isolates, P069, 8146 and GL6, on unstimulated and TNF-stimulated HDMEC under static 
conditions. pRBC, including ItG, were allowed to bind for 1 h to the EC, washed and subsequently incubated in BB without mAb (control) or with 
αICAM-1 mAb at 5 µg/ml and αCD36 mAb at 10 µg/ml or the combination of these mAbs for 1 h. Results expressed as bound pRBC/mm2 ± stand-
ard deviation. **P < 0.01 (compared with group “with TNF”). Binding is also shown to unstimulated (“without TNF”) HDMEC
Page 9 of 13Mustaffa et al. Malar J  (2017) 16:279 
Fig. 6 Reversal of GL6 (a), P069 (b) and 8146 (c) binding on TNF-stimulated HDMEC under flow conditions. pRBC were allowed to bind to the cells 
under flow for 5 min, washed for 2 min and then a solution of BB without mAb (control) or with 5 µg/ml αICAM-1 mAb, 10 µg/ml αCD36 mAb or a 
combination of both was used for to reverse binding. The number of bound pRBC was counted at 5, 10, 15 and 20 min and expressed as percent-
age (%) bound pRBC/mm2 compared to 0 min. *P < 0.05 (compared to 0 min); **P < 0.01 (compared to 0 min)
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immediately once admitted [40–42]. Hence, reversing the 
sequestration of pRBC could be an important approach for 
the development of adjunctive therapy for severe disease. 
The ability of anti-adhesion mediators to not only inhibit, 
but also to reverse adhesion has important therapeutic 
implications. Hughes et  al. have shown cytoadherence of 
pRBC to EC can continue for several hours after admin-
istration of anti-malarial drug treatment [43] despite the 
pRBC being dead. The continuing sequestered parasite 
load has the potential to contribute to disease severity by 
impeding blood flow and causing endothelial damage, as 
well as enhancing local inflammatory responses [44].
In this study, the ability of mAbs to inhibit and reverse 
the cytoadherence of pRBC on purified protein (ICAM-1 
and CD36) and endothelial cells HUVEC and HDMEC 
was assessed. The data demonstrate that αICAM-1 (15.2) 
and αCD36 (FA6-152) mAbs not only highly significantly 
inhibit, but also significantly reverse P. falciparum pRBC 
cytoadherence on protein and EC in vitro, although not 
all isolates showed reversal (e.g. 8146).
Complex interactions of pRBC to the endothelial 
receptors ICAM-1 and CD36 have been shown to occur 
through DBLβ and CIDRα domains of PfEMP1 [45, 46] 
via the N-terminal (domain 1) of ICAM-1 [17] and the 
phosphorylated ectodomain of CD36 respectively [47]. 
The binding of pRBC to ICAM-1 has some overlap with 
that between ICAM-1 and human rhinovirus and LFA-1 
[17], using a similar region of the host receptor for the 
pathogen and the critical host pathway to interact, but 
having variation in the contact residues used. The latter 
is particularly important as the discrimination by mAbs 
between blocking LFA-1 and pRBC binding could be 
important in the design of potential therapies. Blocking 
ICAM-1-dependent interactions has been demonstrated 
by the ability of anti-LFA-1 mAbs to inhibit and reverse 
sequestered leucocytes from endothelium (binding to 
ICAM-1) in murine models, and shows the potential of 
these types of reagents to inhibit and reverse binding, in 
a way that could be applicable to pRBC cytoadherence. 
Therefore, by postulating the same approach to inhibit 
and reverse pRBC binding to ICAM-1, the use of mAbs 
against the surface protein PfEMP1 would seem to be 
warranted. Unfortunately, this is not simple due to the 
high level of variation seen in var genes, which encode 
PfEMP1, although some progress has been made in iden-
tifying conserved PfEMP1 structures responsible for 
EPCR binding [7], which could be used as the basis for 
vaccines. In addition, because not all PfEMP1 variants 
cause SM, finding the appropriate var sequences to use 
for a PfEMP1-based vaccine could be difficult, despite 
recent advances in characterizing conserved regions in 
this family [48]. Therefore, an approach to inhibit pRBC 
adhesion based on the host receptor was considered here.
Anti-ICAM-1 mAb15.2 was chosen because it has been 
used previously and shown to be able to inhibit binding of 
pRBC to ICAM-1 through interaction at loop 42 domain 
of ICAM-1, seen in a range of upsA and upsB PfEMP1 
variants [13, 18]. MAbFA6-152 was chosen based on its 
ability to inhibit pRBC adhesion on CD36, recognizing 
an epitopes within the region 155–183 of CD36 used for 
pRBC binding [49]. The study was initially carried out on 
two laboratory-adapted P. falciparum lines, ItG and C24. 
ItG is a P. falciparum line expressing a PfEMP1 encoded 
by ITvar16, which binds to ICAM-1 strongly, but less to 
CD36, while the C24 line has a PfEMP1 that is encoded 
by ITvar24 and binds to CD36 stronger than ItG, but 
does not bind to ICAM-1.
Both mAbs significantly inhibit pRBC adhesion to 
ICAM-1 and CD36 under static and flow conditions, 
consistent with other studies, but also show the ability 
to reverse existing adhesion, with αICAM-1 mAb more 
effective under flow conditions than αCD36 mAb (Figs. 1, 
2). Following successful reversal and inhibition of bind-
ing to purified protein with both parasite strains, assays 
were carried out using TNF stimulated primary human 
EC (HUVEC and HDMEC). Assays using ItG were con-
ducted using both mAbs individually, and in-combina-
tion (for HDMEC) to observe any cooperative activity 
between these receptors. Cytoadherence under flow con-
ditions is thought to involve multiple adhesion receptors 
acting cooperatively, as shown with CD36, ICAM-1 and 
P-selectin [3, 38, 50]. A model has been widely proposed 
where pRBC are captured from flow by one receptor, roll 
along EC before firm adhesion takes place, possibly being 
mediated by a different receptor. This may separate out 
roles for different receptor families, where a selectin (i.e. 
P-selectin) or Ig superfamily receptor (i.e. ICAM-1) may 
be required to capture PRBC from flow followed by firm 
adhesion to a different class of receptor i.e. CD36. Firm 
adhesion may also require or be enhanced by interactions 
with more than one receptor concurrently (i.e. ICAM-1 
and CD36), and pathology may also require combina-
tions of receptors (i.e. ICAM-1 and EPCR [51]).
Binding of C24 to HDMEC under static conditions 
was inhibited and reversed by ~85% by an αCD36 mAb 
(Fig.  3b, e). Binding of ItG was inhibited by both anti-
bodies individually, and at a similar level when both 
antibodies were used in combination. This suggests 
that either receptor (ICAM-1 and CD36) is required for 
efficient binding for a population of pRBC (Fig.  3c), for 
ItG. The results from reversal experiments using ItG 
illustrated that αICAM-1 mAb and the combination 
(αICAM-1 + αCD36 mAbs) give similar efficacy, whereas 
αCD36 mAb alone is less effective, suggesting that 
ICAM-1 plays a more significant role for binding of this 
ItG line (Fig.  4). These results support observations by 
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McCormick et al., where CD36 was found at lower densi-
ties than ICAM-1 on TNF-stimulated HDMEC [3], and 
suggest that an inhibitor based on a single adhesion com-
ponent might be effective in reducing cytoadherence.
These characteristics were further explored by exam-
ining the ability of the mAbs to reverse recently cul-
ture-adapted patient isolates (GL6, P069 and 8146) 
in comparison with the laboratory parasite line (ItG) 
(Fig.  5). The results show that the αICAM-1 mAb was 
more effective at reversing binding than αCD36 mAb 
under flow and static conditions for GL6 and PO69, but 
at a lower level compared to ItG. In one case (8146) there 
was almost no reversal of adhesion, which was different 
from previously published results [19] and may indicate 
a mixed population due to PfEMP1 switching during 
in  vitro culture. This suggests that the clinical isolates 
tested might be expressing PfEMP1 variants with pos-
sibly more extensive repertoires of host receptor bind-
ing and highlights a challenge of using anti-adhesion 
approaches for therapy due to the need to include inhibi-
tion of multiple receptors. Further work will be needed to 
identify whether reasonable coverage could be achieved 
in reversing cytoadherence using inhibitors based one or 
two specific receptors (i.e. ICAM-1 and EPCR).
Several previous studies have shown that antibod-
ies can work through inhibiting the binding of pRBC to 
specific receptors but have not looked at their ability to 
reverse established cytoadherence, despite this being the 
likely situation encountered for an adjunct therapy. To 
reverse existing adhesion, it is necessary that the affinity 
of mAbs for the corresponding receptor is higher than 
that of the PfEMP1/host receptor interaction. Measure-
ments of PfEMP1/receptor  Kd are around 1–100 nM [7, 
52] (the ITvar16 (ItG)/ICAM-1  Kd is 51.1 nM) and mouse 
monoclonal mAbs have  Kd values in the low nM to sub-
nM range so it might be expected that the equilibrium of 
mAb and pRBC ligand for the receptor would allow the 
antibody to compete for the functional binding site, free-
ing the bound pRBC into the microvasculature [33]. The 
type of antibody needs to be chosen carefully, as it should 
not interfere with the physiological role of the specific 
endothelial receptor. However, the multivalent interac-
tion of pRBC with EC could compete well with mAbs 
(or inhibitors) in solution, therefore reversing adhesion 
in vivo could be a challenge, which supports the relatively 
slow loss of pRBC from the EC under flow seen here for 
some parasite isolates.
The data demonstrate that mAbs can both inhibit 
and reverse binding under static and flow conditions, 
albeit with only partial reversal seen with patient iso-
lates. Whilst this gives some support for the concept 
of an anti-adhesion therapy, which could minimize the 
severe complications of falciparum malaria, there are 
limitations on the design of these inhibitors, in particu-
lar the need for high affinity to compete with PfEMP1/
host interactions. With cerebral malaria patients, the 
intravenous introduction of adhesion-blocking sub-
stances could not only lead to reversal of sequestration, 
but may also prevent the onset of brain swelling in cer-
ebral malaria [53] through reducing pRBC-induced 
endothelial activation.
The results suggest that SM might be managed through 
anti-adhesion therapy, but it needs to be borne in mind 
that as well as being receptors for parasite adhesion, 
ICAM-1 and CD36 play major roles in leukocyte traffick-
ing and normal human immune system responses. It has 
been shown that in blocking the receptor protein for the 
pathogen, this might inhibit the normal function of the 
protein and possibly affect the host [54]. Therefore, while 
these experiments might show the concept of anti-adhe-
sion development based on receptor competition, fur-
ther work should be considered for the development of 
anti-adhesion therapies based on specificity for the pRBC 
interaction, high affinity and, for practical reasons, cost of 
goods. Consideration about the effect of releasing many 
rigid pRBC into the spleen also needs to be given. Taken 
together, these represent barriers to the development of 
anti-adhesion adjunct therapies, although interpretation 
of the results obtain in this paper needs some caution as 
only at a limited number of parasite lines were examined 
and only for the receptors ICAM-1 and CD36. Also, anti-
adhesion strategies may be able to directly reduce pathol-
ogy, for example by removing EPCR-binding infected 
erythrocytes from the activated protein C generating site 
on EPCR.
While the ability to reverse existing pRBC cytoadher-
ence to EC has been demonstrated in this paper, the 
results suggest that looking at other approaches such as 
those based on mitigating the effects of cytoadherence 
on the vasculature, rather than the adhesion itself or the 
induction of cross-reactive immunity to binding by vac-
cination, may be more viable approaches. Further work 
on a more extensive panel of parasite lines and receptor 
combinations is required, but the integration of rever-
sal assays into anti-adhesion product development is 
warranted.
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